eXmoor Pharma
Bristol, United Kingdom
1 partnership announcement in press monitoring
· Last scored 2026-09-07
78.1
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (3)
○ EMA GMP
✓ MHRA GMP (1)
Quick Facts: eXmoor Pharma
- Signal Score
- 78.1/100 (as of 2026-09-07)
- Quality Compliance
- 100.0/100
- Headquarters
- Bristol, United Kingdom
- Modalities
- Cell Therapy, AAV
- Active Programs
- Data pending
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About eXmoor Pharma
Pure-play CDMO.
Signal Score & Pillar Breakdown
Scores are being republished.
Scores are being republished under methodology v3.3. The score shown is the last complete v3.2 result, which is also what directory listings and search results show. A pillar breakdown is not shown because the current one is computed under v3.3 and would not explain a v3.2 score. Regulatory evidence below is current.
Quality Compliance
100.0
FDA InspectionsNo US records on file
MHRA GMP Certificates1 on record
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer. 1 partnership announcement found in press monitoring.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCell Therapy, AAV
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Partnership Announcements (from press monitoring)
Financial Stability
60.0
Profile-based financial assessment
SEC FilingsPrivate company
Capacity
58.0
Profile-based capacity assessment
Recent Press3 articles
eXmoor Pharma MHRA GMP Compliance 1 certificates
2025-11
Compliant
Non-Compliant
| Certificate | Site | City / Postcode | Inspection Date | Status |
|---|---|---|---|---|
| UK MIA(IMP) 32954 Insp GMP/IMP 32954/36082496-0002[I] | EXMOOR PHARMA CONCEPTS LTD | BRISTOL BS34 5TA | 2025-11-12 | COMPLIANT |
Source: MHRA GMDP Database · Retrieved Oct 08, 2026
Recent News 3 articles
eXmoor Pharma and Royal Free London’s CVIC Form Strategic Partnership to Streamline UK Cell and Gene Therapy Manufacturing - BioPharma APAC
eXmoor Pharma and Royal Free London’s CVIC Form Strategic Partnership to Streamline UK Cell and Gene Therapy Manufacturing BioPharma APAC
eXmoor Pharma appoints Manuel Balbuena as Chief Commercial Officer - Pharmafile
eXmoor Pharma appoints Manuel Balbuena as Chief Commercial Officer Pharmafile
eXmoor Pharma Appoints Manuel Balbuena Chief Commercial Officer - Contract Pharma
eXmoor Pharma Appoints Manuel Balbuena Chief Commercial Officer Contract Pharma
Frequently Asked Questions About eXmoor Pharma
Does eXmoor Pharma hold EMA or MHRA GMP certificates?
CDMO Signal tracks 1 MHRA GMP certificate for eXmoor Pharma.
What is eXmoor Pharma's CDMO Signal Score?
eXmoor Pharma has a Signal Score of 78/100, based on quality, operations, financial stability, and capacity data.
Evaluating eXmoor Pharma for a manufacturing program?
Use the free AI matchmaker to compare eXmoor Pharma against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Cell and Gene Therapy Catapult
Stevenage, United Kingdom
Signal Score: 59.0
CAR-T, Cell Therapy, AAV
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 90.9
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
WuXi Biologics
Shanghai, CN · Wuxi, CN
Signal Score: 82.9
CAR-T, Cell Therapy, AAV, ADC, Monoclonal Antibody
Takeda
Boston, MA · Zurich, CH
Signal Score: 81.9
AAV, Cell Therapy
Danaher (CGT Portfolio)
Washington, DC
Signal Score: 81.5
Cell Therapy, AAV, mRNA